Instil Bio, Inc. (TIL) stock
TILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.40−0.35 (-6.09%)
Close on Nov 17, 2026Market cap $36.62MP/E –Yield –
Instil Bio operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Instil Bio's operating income for the twelve months ending Jun 30, 2026 was -$37.17M. For fiscal 2025 it was -$78.58M. The highest annual figure on record is -$33.64M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$78.58M | – |
| FY2024 | Dec 31, 2024 | -$73.54M | – |
| FY2023 | Dec 31, 2023 | -$159.17M | – |
| FY2022 | Dec 31, 2022 | -$226.46M | – |
| FY2021 | Dec 31, 2021 | -$155.56M | – |
| FY2020 | Dec 31, 2020 | -$33.64M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$5.58M | – |
| Q1 FY2026 | Mar 31, 2026 | -$7.01M | – |
| Q4 FY2025 | Dec 31, 2025 | -$9.56M | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.02M | – |
| Q2 FY2025 | Jun 30, 2025 | -$23.44M | – |
| Q1 FY2025 | Mar 31, 2025 | -$30.56M | – |
| Q4 FY2024 | Dec 31, 2024 | -$11.82M | – |
| Q3 FY2024 | Sep 30, 2024 | -$23.63M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.14M | – |
| Q1 FY2024 | Mar 31, 2024 | -$23.96M | – |
| Q4 FY2023 | Dec 31, 2023 | -$13.02M | – |
| Q3 FY2023 | Sep 30, 2023 | -$66.72M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.99M | – |
| Q1 FY2023 | Mar 31, 2023 | -$58.45M | – |
| Q4 FY2022 | Dec 31, 2022 | -$56.80M | – |
| Q3 FY2022 | Sep 30, 2022 | -$56.65M | – |
| Q2 FY2022 | Jun 30, 2022 | -$58.72M | – |
| Q1 FY2022 | Mar 31, 2022 | -$54.29M | – |
| Q4 FY2021 | Dec 31, 2021 | -$53.75M | – |
| Q3 FY2021 | Sep 30, 2021 | -$43.02M | – |
| Q2 FY2021 | Jun 30, 2021 | -$35.38M | – |
| Q1 FY2021 | Mar 31, 2021 | -$23.40M | – |
| Q4 FY2020 | Dec 31, 2020 | -$17.48M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.71M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.59M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.86M | – |
See a number that looks wrong?